[Form 3] Kindly MD, Inc. Initial Statement of Beneficial Ownership
Kindly MD, Inc. (NAKA) reporting person Andrew Creighton disclosed direct beneficial ownership of 892,857 shares of common stock on a Form 3 filed for the 08/14/2025 event. The filing identifies Mr. Creighton as a director and as Chief Compliance Officer and is signed 08/19/2025. The Form 3 documents initial ownership and includes Exhibit 24 (Power of Attorney).
Kindly MD, Inc. (NAKA), con la persona che presenta la comunicazione Andrew Creighton, ha dichiarato la proprietà beneficiaria diretta di 892.857 azioni ordinarie in un Modulo 3 depositato per l'evento del 14/08/2025. Il deposito identifica il Sig. Creighton come amministratore e Chief Compliance Officer ed è firmato il 19/08/2025. Il Modulo 3 documenta la proprietà iniziale e include l'Allegato 24 (Procura).
Kindly MD, Inc. (NAKA), persona informante Andrew Creighton, declaró la propiedad beneficiaria directa de 892.857 acciones ordinarias en un Formulario 3 presentado por el evento del 14/08/2025. La presentación identifica al Sr. Creighton como director y Chief Compliance Officer y está firmada el 19/08/2025. El Formulario 3 documenta la titularidad inicial e incluye el Anexo 24 (Poder).
Kindly MD, Inc. (NAKA) 신고인 Andrew Creighton는 2025년 8월 14일 사건과 관련해 보통주 892,857주에 대한 직접적 실소유를 Form 3에 공시했습니다. 제출 서류는 Creighton 씨를 이사이자 최고준법감시인(Chief Compliance Officer)으로 명시하고 있으며 2025년 8월 19일 서명되었습니다. Form 3은 초기 소유를 문서화하고 부속서류 24(위임장)를 포함합니다.
Kindly MD, Inc. (NAKA), la personne déclarante Andrew Creighton, a déclaré la propriété bénéficiaire directe de 892 857 actions ordinaires dans un Formulaire 3 déposé pour l'événement du 14/08/2025. Le dépôt identifie M. Creighton comme administrateur et Chief Compliance Officer et est signé le 19/08/2025. Le Formulaire 3 consigne la détention initiale et comprend l'Annexe 24 (Procuration).
Kindly MD, Inc. (NAKA) meldende Person Andrew Creighton gab in einem am 14.08.2025 eingereichten Formular 3 den direkten wirtschaftlichen Besitz von 892.857 Stammaktien bekannt. Die Einreichung nennt Herrn Creighton als Director und Chief Compliance Officer und ist am 19.08.2025 unterschrieben. Das Formular 3 dokumentiert das anfängliche Eigentum und enthält Anlage 24 (Vollmacht).
- Disclosure of direct beneficial ownership of 892,857 common shares
- Reporting person identified as Director and Chief Compliance Officer, improving transparency
- Form signed and dated (08/19/2025) and references Exhibit 24 (Power of Attorney)
- None.
Insights
TL;DR: Initial insider disclosure shows a substantial direct stake of 892,857 shares by a director/officer, a neutral routine compliance filing.
The Form 3 reports an initial ownership position by Andrew Creighton of 892,857 common shares, filed under Section 16. This is a standard Section 16 filing that increases transparency about insider holdings. There is no transaction, option grant, or derivative disclosed here—only direct common stock ownership. For investors, the filing confirms insider alignment with the company but contains no operational or financial metrics to reassess valuation.
TL;DR: A routine initial beneficial ownership filing by an officer/director; governance disclosure appears complete with POA exhibit referenced.
The report identifies Mr. Creighton as both a director and the Chief Compliance Officer and attaches Exhibit 24 (Power of Attorney), suggesting proper execution and representation. The filing is signed and dated, meeting Section 16(a) reporting requirements. No amendments or joint filers are indicated. The disclosure supports compliance standards but does not signal governance changes or transactions.
Kindly MD, Inc. (NAKA), con la persona che presenta la comunicazione Andrew Creighton, ha dichiarato la proprietà beneficiaria diretta di 892.857 azioni ordinarie in un Modulo 3 depositato per l'evento del 14/08/2025. Il deposito identifica il Sig. Creighton come amministratore e Chief Compliance Officer ed è firmato il 19/08/2025. Il Modulo 3 documenta la proprietà iniziale e include l'Allegato 24 (Procura).
Kindly MD, Inc. (NAKA), persona informante Andrew Creighton, declaró la propiedad beneficiaria directa de 892.857 acciones ordinarias en un Formulario 3 presentado por el evento del 14/08/2025. La presentación identifica al Sr. Creighton como director y Chief Compliance Officer y está firmada el 19/08/2025. El Formulario 3 documenta la titularidad inicial e incluye el Anexo 24 (Poder).
Kindly MD, Inc. (NAKA) 신고인 Andrew Creighton는 2025년 8월 14일 사건과 관련해 보통주 892,857주에 대한 직접적 실소유를 Form 3에 공시했습니다. 제출 서류는 Creighton 씨를 이사이자 최고준법감시인(Chief Compliance Officer)으로 명시하고 있으며 2025년 8월 19일 서명되었습니다. Form 3은 초기 소유를 문서화하고 부속서류 24(위임장)를 포함합니다.
Kindly MD, Inc. (NAKA), la personne déclarante Andrew Creighton, a déclaré la propriété bénéficiaire directe de 892 857 actions ordinaires dans un Formulaire 3 déposé pour l'événement du 14/08/2025. Le dépôt identifie M. Creighton comme administrateur et Chief Compliance Officer et est signé le 19/08/2025. Le Formulaire 3 consigne la détention initiale et comprend l'Annexe 24 (Procuration).
Kindly MD, Inc. (NAKA) meldende Person Andrew Creighton gab in einem am 14.08.2025 eingereichten Formular 3 den direkten wirtschaftlichen Besitz von 892.857 Stammaktien bekannt. Die Einreichung nennt Herrn Creighton als Director und Chief Compliance Officer und ist am 19.08.2025 unterschrieben. Das Formular 3 dokumentiert das anfängliche Eigentum und enthält Anlage 24 (Vollmacht).